Domestic pharmaceutical companies focus on development of salt-modified drugs and generics of ‘Viread’

The hepatitis B therapy which recorded KRW 125.3 billion prescriptions in Korea last year, Viread(generic name: tenofovir, Gilead), will be expired in patent. Thus, pharmaceutical companies preparing for generics related to the drug are getting busier as well.

Domestic companies are getting ready for the market entry after the Viread patent expiration, divided into two tracks: clinical trials ...